Shares of Anika Therapeutics (ANIK) - Get Report were up 4.62%, or $2.16, to $48.88 on a report from Zacks that analysts following the company are maintaining strong buy ratings on the company and have a one year consensus target price of $52.00 and predict it will earn 49 cents per share this quarter. Anika focuses on pain management, tissue regeneration and wound healing. Zacks Investment Research also has a buy rating and set a $55.00 target price on the stock in in February. A number of institutional investors have increased their holdings in Anika, including Victory Capital, Municipal Employees Retirement System of Michigan, Mason Street Advisors and Ladenburg Thalmann. Envestnet Asset Management purchased a new position in shares of Anika Therapeutics during the first quarter worth about $204,000.
Supernus Pharmaceuticals (SUPN) - Get Report was down 1.2% to $33. Jefferies Group dropped its first quarter 2017 earnings per share Tuesday. Jefferies, however, has a buy rating and a $35.00 target price on the stock. Cantor Fitzgerald reaffirmed an overweight rating with a $34.00 price target Thursday. Also Thursday Cowen and Company reaffirmed an outperform rating and set a $40.00 price target, up previously from $33.00. On Tuesday Supernus reported net income for the first quarter of $10.3 million or $0.19 per diluted share as compared to net income of $4.8 million or $0.08 per diluted share in the first quarter of 2016.
Cytokinetics (CYTK) - Get Report are up 1.06% to $14.35. The FDA has designated CK-2127107, a fast skeletal troponin activator, as an Orphan Drug for the treatment of spinal muscular atrophy. On Friday, May the company is scheduled to close a public offering of 5.26 million shares at $14.25 per share. Proceeds to Cytokinetics are expected to be to be approximately $75.0 million